Learn about our latest activities
On October 9, 2021, NOVAST received our FIRST Approval notice from China NMPA. In accordance with the relevant provisions of the Drug Administration Law, Metformin Hydrochloride Sustained-release Tablets (III )(1.0g)developed by NOVAST was approved by China NMPA, which marked the FIRST breakthrough of NMPA product approval for NOVAST.